The combination of all these factors in NASH may be responsible for the persistent activation of SREBP2, bypassing the inhibitory effect of high cellular cholesterol levels that develop through a negative feedback mechanism [103,104]. This evidence concerns the gene SREBF2 and metabolic dysfunction-associated steatohepatitis.